was read the article
array:24 [ "pii" => "S0873215915302889" "issn" => "08732159" "doi" => "10.1016/S0873-2159(15)30288-9" "estado" => "S350" "fechaPublicacion" => "2008-11-01" "aid" => "6" "copyright" => "Sociedade Portuguesa de Pneumologia/SPP" "copyrightAnyo" => "2008" "documento" => "simple-article" "crossmark" => 0 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "fla" "cita" => "Rev Port Pneumol. 2008;14:803-27" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 3013 "formatos" => array:3 [ "EPUB" => 237 "HTML" => 2041 "PDF" => 735 ] ] "itemSiguiente" => array:19 [ "pii" => "S0873215915302890" "issn" => "08732159" "doi" => "10.1016/S0873-2159(15)30289-0" "estado" => "S350" "fechaPublicacion" => "2008-11-01" "aid" => "7" "copyright" => "Sociedade Portuguesa de Pneumologia/SPP" "documento" => "simple-article" "crossmark" => 0 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "fla" "cita" => "Rev Port Pneumol. 2008;14:829-42" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 2425 "formatos" => array:3 [ "EPUB" => 243 "HTML" => 1487 "PDF" => 695 ] ] "pt" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Artigo Original/Original Article</span>" "titulo" => "Análise comparativa entre tuberculose multirresistente e tuberculose extensivamente resistente – Epidemiologia e factores preditivos" "tienePdf" => "pt" "tieneTextoCompleto" => 0 "tieneResumen" => array:2 [ 0 => "pt" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "829" "paginaFinal" => "842" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Comparative analysis of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis – Epidemiology and predictive factors" ] ] "contieneResumen" => array:2 [ "pt" => true "en" => true ] "contienePdf" => array:1 [ "pt" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Ana Sofia Vilariça, Carlos Gomes, Jaime Pina" "autores" => array:3 [ 0 => array:2 [ "nombre" => "Ana" "apellidos" => "Sofia Vilariça" ] 1 => array:2 [ "nombre" => "Carlos" "apellidos" => "Gomes" ] 2 => array:2 [ "nombre" => "Jaime" "apellidos" => "Pina" ] ] ] ] ] "idiomaDefecto" => "pt" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0873215915302890?idApp=UINPBA00004E" "url" => "/08732159/0000001400000006/v1_201509151433/S0873215915302890/v1_201509151433/pt/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S0873215915302877" "issn" => "08732159" "doi" => "10.1016/S0873-2159(15)30287-7" "estado" => "S350" "fechaPublicacion" => "2008-11-01" "aid" => "5" "copyright" => "Sociedade Portuguesa de Pneumologia/SPP" "documento" => "simple-article" "crossmark" => 0 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "fla" "cita" => "Rev Port Pneumol. 2008;14:787-802" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 2509 "formatos" => array:3 [ "EPUB" => 220 "HTML" => 1540 "PDF" => 749 ] ] "pt" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Artigo Original/Original Article</span>" "titulo" => "Corpos estranhos na via aérea: Experiência de um quarto de século" "tienePdf" => "pt" "tieneTextoCompleto" => 0 "tieneResumen" => array:2 [ 0 => "pt" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "787" "paginaFinal" => "802" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Foreign bodies in the airway: A quarter of a century’s experience" ] ] "contieneResumen" => array:2 [ "pt" => true "en" => true ] "contienePdf" => array:1 [ "pt" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Juliana Roda, Susana Nobre, Jorge Pires, M. Helena Estêvão, Miguel Félix" "autores" => array:5 [ 0 => array:2 [ "nombre" => "Juliana" "apellidos" => "Roda" ] 1 => array:2 [ "nombre" => "Susana" "apellidos" => "Nobre" ] 2 => array:2 [ "nombre" => "Jorge" "apellidos" => "Pires" ] 3 => array:2 [ "nombre" => "M. Helena" "apellidos" => "Estêvão" ] 4 => array:2 [ "nombre" => "Miguel" "apellidos" => "Félix" ] ] ] ] ] "idiomaDefecto" => "pt" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0873215915302877?idApp=UINPBA00004E" "url" => "/08732159/0000001400000006/v1_201509151433/S0873215915302877/v1_201509151433/pt/main.assets" ] "pt" => array:15 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Artigo Original/Original Article</span>" "titulo" => "Avaliação económica do erlotinib, docetaxel, pemetrexedo e tratamento de suporte no tratamento de segunda ou terceira linhas de doentes com cancro do pulmão de não pequenas células" "tieneTextoCompleto" => 0 "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "803" "paginaFinal" => "827" ] ] "autores" => array:1 [ 0 => array:3 [ "autoresLista" => "A. Araújo, B. Parente, R. Sotto-Mayor, E. Teixeira, T. Almodôvar, F. Barata, H. Queiroga, C. Pereira, H. Pereira, F. Negreiro, C. Silva" "autores" => array:11 [ 0 => array:3 [ "nombre" => "A." "apellidos" => "Araújo" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">1</span>" "identificador" => "af0005" ] ] ] 1 => array:3 [ "nombre" => "B." "apellidos" => "Parente" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">2</span>" "identificador" => "af0010" ] ] ] 2 => array:3 [ "nombre" => "R." "apellidos" => "Sotto-Mayor" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">3</span>" "identificador" => "af0015" ] ] ] 3 => array:3 [ "nombre" => "E." "apellidos" => "Teixeira" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">4</span>" "identificador" => "af0020" ] ] ] 4 => array:3 [ "nombre" => "T." "apellidos" => "Almodôvar" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">5</span>" "identificador" => "af0025" ] ] ] 5 => array:3 [ "nombre" => "F." "apellidos" => "Barata" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">6</span>" "identificador" => "af0030" ] ] ] 6 => array:3 [ "nombre" => "H." "apellidos" => "Queiroga" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">7</span>" "identificador" => "af0035" ] ] ] 7 => array:3 [ "nombre" => "C." "apellidos" => "Pereira" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">8</span>" "identificador" => "af0040" ] ] ] 8 => array:3 [ "nombre" => "H." "apellidos" => "Pereira" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">9</span>" "identificador" => "af0045" ] ] ] 9 => array:3 [ "nombre" => "F." "apellidos" => "Negreiro" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">10</span>" "identificador" => "af0050" ] ] ] 10 => array:3 [ "nombre" => "C." "apellidos" => "Silva" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">11</span>" "identificador" => "af0055" ] ] ] ] "afiliaciones" => array:11 [ 0 => array:3 [ "entidad" => "Coordenador da Clínica de Patologia do Pulmão, Serviço de Oncologia Médica, Instituto Português de Oncologia Francisco Gentil – Centro do Porto, Portugal / Francisco Gentil Portuguese Oncology Institute, Centro do Porto, Lung Pathology Clinic Coordinator, Medical Oncology Unit, Porto, Portugal" "etiqueta" => "1" "identificador" => "af0005" ] 1 => array:3 [ "entidad" => "Directora do Serviço de Pneumologia, Serviço de Pneumologia, Centro Hospitalar de V. N. Gaia, Portugal / Centro Hospitalar de V. N. Gaia, Head, Pulmonology Unit, Pulmonology Unit, V. N. Gaia, Portugal" "etiqueta" => "2" "identificador" => "af0010" ] 2 => array:3 [ "entidad" => "Chefe de Serviço de Pneumologia, Serviço de Pneumologia do Hospital de Santa Maria, CHLN, Lisboa, Portugal / Head, Pulmonology Unit, Pulmonology Unit, Hospital de Santa Maria, CHLN, Lisbon, Portugal" "etiqueta" => "3" "identificador" => "af0015" ] 3 => array:3 [ "entidad" => "Assistente Graduada de Pneumologia, Serviço de Pneumologia, Hospital de Santa Maria, Lisboa, Portugal / Hospital de Santa Maria, Consultant, Pulmonology specialist, Pulmonology Unit, Lisbon, Portugal" "etiqueta" => "4" "identificador" => "af0020" ] 4 => array:3 [ "entidad" => "Serviço de Pneumologia; Instituto Português de Oncologia de Francisco Gentil, Lisboa, Portugal / Pulmonology Unit, Francisco Gentil Portuguese Oncology Institute, Lisbon, Portugal" "etiqueta" => "5" "identificador" => "af0025" ] 5 => array:3 [ "entidad" => "Responsável de Pneumologia Oncológica, Centro Hospitalar de Coimbra, Portugal / Head, Pulmonary Oncology, Centro Hospitalar de Coimbra, Portugal" "etiqueta" => "6" "identificador" => "af0030" ] 6 => array:3 [ "entidad" => "Coordenador da Consulta de Pneumologia Oncológica, Hospital de S. João, Porto; Portugal / Pulmonary Oncology Appointment Coordinator, Hospital de S. João, Porto, Portugal" "etiqueta" => "7" "identificador" => "af0035" ] 7 => array:3 [ "entidad" => "<span class="elsevierStyleItalic">Pharmacoeconomic Manager</span>, Departamento de Market Access & Health Economics, Roche Farmacêutica Química, Lda.; Portugal / Pharmacoeconomic Manager, Market Access & Health Economics Unit, Roche Farmacêutica Química, Lda., Portugal" "etiqueta" => "8" "identificador" => "af0040" ] 8 => array:3 [ "entidad" => "<span class="elsevierStyleItalic">Medical Manager</span> Oncologia Pulmão, Roche Farmacêutica Química, Lda., Portugal / Medical Manager, Pulmonary Oncology, Roche Farmacêutica Química, Lda., Portugal" "etiqueta" => "9" "identificador" => "af0045" ] 9 => array:3 [ "entidad" => "Bioestatista, <span class="elsevierStyleItalic">Eurotrials</span> - Consultores Científicos, Lisboa, Portugal / Biostatistician, Eurotrials - Consultores Científicos, Lisbon, Portugal" "etiqueta" => "10" "identificador" => "af0050" ] 10 => array:3 [ "entidad" => "Bioestatista Sénior, Eurotrials - Consultores Científicos, Lisboa; Portugal / Senior Biostatistician, Eurotrials - Consultores Científicos, Lisbon, Portugal" "etiqueta" => "11" "identificador" => "af0055" ] ] ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "An economic analysis of erlotinib, docetaxel, pemetrexed and best supportive care as second or third line treatment of non-small cell lung cancer" ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2008-08-22" "fechaAceptado" => "2008-09-11" "PalabrasClave" => array:2 [ "pt" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palavras-chave" "identificador" => "xpalclavsec570064" "palabras" => array:5 [ 0 => "Cancro do pulmão de não pequenas células" 1 => "económico" 2 => "Portugal" 3 => "utilidade" 4 => "custo-efectividade" ] ] ] "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Key-words" "identificador" => "xpalclavsec570065" "palabras" => array:5 [ 0 => "Non-small cell lung cancer" 1 => "economics" 2 => "Portugal" 3 => "utility" 4 => "cost-effectiveness" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "pt" => array:2 [ "titulo" => "Resumo" "resumen" => "<span id="as0005" class="elsevierStyleSection elsevierViewall"><p id="sp0005" class="elsevierStyleSimplePara elsevierViewall"><span class="elsevierStyleBold">Objectivo:</span> Avaliar o custo-efectividade de erlotinib na segunda ou terceira linha do tratamento do cancro do pulmão de não pequenas células (CPNPC) avançado ou metastizado <span class="elsevierStyleItalic">versus</span> docetaxel, pemetrexedo ou tratamento de suporte.</p><p id="sp0010" class="elsevierStyleSimplePara elsevierViewall"><span class="elsevierStyleBold">Material e métodos:</span> Análises de minimização de custos e custo-utilidade. Horizonte temporal: dois anos. Perspectiva do Sistema Nacional de Saúde (SNS) português. Sobrevivência e tempo até progressão obtidos a partir de três ensaios clínicos. Análise-base inclui doentes com CPNPC avançado ou metastizado em segunda ou terceira linhas. Anos de vida ajustados pela qualidade (ou QALY) obtidos a partir de estudo no Reino Unido. Consumo de recursos estimado por painel de peritos portugueses. Incluíram-se apenas custos directos, obtidos a partir de fontes oficiais (preços actualizados para 2008). Taxa de actualização anual: 5%. Análises de sensibilidade: diferentes subpopulações, horizonte temporal a três anos e análise probabilística.</p><p id="sp0015" class="elsevierStyleSimplePara elsevierViewall"><span class="elsevierStyleBold">Resultados:</span> O custo total/doente foi menor com erlotinib (26 478€) <span class="elsevierStyleItalic">versus</span> docetaxel (29 262€) ou pemetrexedo (32 762€) e superior <span class="elsevierStyleItalic">versus</span> tratamento de suporte (16 112€). Obtiveram-se QALY/doente mais elevados com erlotinib (0,250) <span class="elsevierStyleItalic">versus</span> docetaxel (0,225), pemetrexedo (0,241) ou tratamento de suporte (0,186). Assim, o erlotinib mostrou-se “dominante” em segunda ou terceira linhas <span class="elsevierStyleItalic">versus</span> docetaxel e pemetrexedo. A análise de sensibilidade comprova a robustez dos resultados.</p><p id="sp0020" class="elsevierStyleSimplePara elsevierViewall"><span class="elsevierStyleBold">Conclusões:</span> A substituição de docetaxel ou pemetrexedo por erlotinib poderia contribuir para uma redução anual dos gastos do SNS que se estima (taxas substituição: 5%-65%) com uma variação entre 135 046€-1 755 602€ e entre 291 801€-3 793 409€, respectivamente, e com ganho em termos de QALY.</p><p id="sp0025" class="elsevierStyleSimplePara elsevierViewall"><span class="elsevierStyleBold">Rev Port Pneumol 2008; XIV (6): 803-827</span></p></span>" ] "en" => array:2 [ "titulo" => "Abstract" "resumen" => "<span id="as0010" class="elsevierStyleSection elsevierViewall"><p id="sp0030" class="elsevierStyleSimplePara elsevierViewall"><span class="elsevierStyleBold">Aim:</span> Evaluate costs and benefits of erlotinib as 2<span class="elsevierStyleSup">nd</span> or 3<span class="elsevierStyleSup">rd</span> line treatment of advanced or metastatic nonsmall cell lung cancer (NSCLC) <span class="elsevierStyleItalic">versus</span> docetaxel, pemetrexed and best supportive care.</p><p id="sp0035" class="elsevierStyleSimplePara elsevierViewall"><span class="elsevierStyleBold">Materials and methods:</span> Cost-minimisation and cost-utility analysis were performed. Time horizon of two years. Portuguese National Health System (NHS) perspective was applied. Survival and time to progression were obtained from three clinical trials. Base-case analysis: 2<span class="elsevierStyleSup">nd</span> or 3<span class="elsevierStyleSup">rd</span> line patients with advanced or metastatic NSCLC. Quality Adjusted Life Years (QALYs) were obtained from a UK study. Resource consumption was estimated by a Portuguese panel of experts. Costs were calculated according to official Portuguese databases (updated to 2008). Only direct health costs were applied. Annual discount rate: 5%. Sensitivity analysis included different subpopulations, a three year time horizon and a probabilistic analysis.</p><p id="sp0040" class="elsevierStyleSimplePara elsevierViewall"><span class="elsevierStyleBold">Results:</span> The cost per patient was lower with erlotinib (€26 478) than docetaxel (€29 262) or pemetrexed (€32 762) and higher than best supportive care (€16 112). QALYs per patient were higher with erlotinib (0.250) than docetaxel (0.225), pemetrexed (0.241) or best supportive care (0.186). Erlotinib was dominant in the cost-utility analysis, with a lower cost and a higher efficacy than docetaxel and pemetrexed. The sensitivity analysis confirmed the robustness of the base-case analysis results.</p><p id="sp0045" class="elsevierStyleSimplePara elsevierViewall"><span class="elsevierStyleBold">Conclusions:</span> The use of erlotinib instead of docetaxel or pemetrexed could contribute to annual savings for the NHS (substitution rates: 5%-65%) ranging from €135 046-€1 755 602 (docetaxel replacement) and €291 801-€3 793 409 (pemetrexed replacement), with a gain in terms of QALYs.</p><p id="sp0050" class="elsevierStyleSimplePara elsevierViewall"><span class="elsevierStyleBold">Rev Port Pneumol 2008; XIV (6): 803-827</span></p></span>" ] ] "lecturaRecomendada" => array:1 [ 0 => array:3 [ "vista" => "all" "titulo" => "<span class="elsevierStyleSectionTitle" id="st0025">Bibliografia / Bibliography</span>" "seccion" => array:1 [ 0 => array:2 [ "vista" => "all" "bibliografiaReferencia" => array:14 [ 0 => array:3 [ "identificador" => "bb0005" "etiqueta" => "1." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "Non-Small Cell Lung Cancer Collaborative Group" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "BMJ" "fecha" => "1995" "volumen" => "311" "paginaInicial" => "899" "paginaFinal" => "909" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/7580546" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bb0010" "etiqueta" => "2." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Estudo epidemiológico do cancro do pulmão em Portugal nos anos 2000/2002" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:4 [ 0 => "B. Parente" 1 => "H. Queiroga" 2 => "E. Teixeira" 3 => "R. Sotto-Mayor" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Rev Port Pneumol" "fecha" => "2007" "volumen" => "XIII" "numero" => "2" "paginaInicial" => "255" "paginaFinal" => "265" ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bb0015" "etiqueta" => "3." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Henrique Barros, Nuno Lunet, Manuel Sobrinho Simões. O Cancro em Portugal. Disponível em<a href="http://www.ipatimup.pt/medprev/paper3.pdf">http://www.ipatimup.pt/medprev/paper3.pdf</a>." ] ] ] 3 => array:3 [ "identificador" => "bb0020" "etiqueta" => "4." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Valutazione económica di erlotinib, docetaxel e pemetrexed nel trattamento di seconda línea del carcinoma polmonare non a piccole cellule" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "S. Capri" 1 => "A. Morabito" 2 => "G. Carillio" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "PharmacoEconomics – Italian Research Articles" "fecha" => "2007" "volumen" => "9" "numero" => "2" "paginaInicial" => "113" "paginaFinal" => "124" ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bb0025" "etiqueta" => "5." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Resumo das Características do Medicamento Tarceva®. Disponível em <a href="http://www.emea.europa.eu/hu-mandocs/PDFs/EPAR/tarceva/H">http://www.emea.europa.eu/hu-mandocs/PDFs/EPAR/tarceva/H</a> -618-PI-pt.pdf; consulta em Julho 2008." ] ] ] 5 => array:3 [ "identificador" => "bb0030" "etiqueta" => "6." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "F.A. Shepherd" 1 => "J. Dancey" 2 => "R. Ramlau" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Clin Onc" "fecha" => "2000" "volumen" => "18" "numero" => "10" "paginaInicial" => "2095" "paginaFinal" => "2103" ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bb0035" "etiqueta" => "7." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "N. Hanna" 1 => "F.A. Shepherd" 2 => "F.V. Fossella" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Clin Onc" "fecha" => "2004" "volumen" => "22" "numero" => "9" "paginaInicial" => "1589" "paginaFinal" => "1597" ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bb0040" "etiqueta" => "8." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:19 [ 0 => "F.A. Shepherd" 1 => "J. Rodrigues Pereira" 2 => "T. Ciuleanu" 3 => "E.H. Tan" 4 => "V. Hirsh" 5 => "S. Thongprasert" 6 => "D. Campos" 7 => "S. Maoleekoonpiroj" 8 => "M. Smylie" 9 => "R. Martins" 10 => "M. van Kooten" 11 => "M. Dediu" 12 => "B. Findlay" 13 => "D. Tu" 14 => "D. Johnston" 15 => "A. Bezjak" 16 => "G. Clark" 17 => "P. Santabárbara" 18 => "L. Seymour" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa050753" "Revista" => array:7 [ "tituloSerie" => "N Engl J Med" "fecha" => "2005" "volumen" => "353" "numero" => "2" "paginaInicial" => "123" "paginaFinal" => "132" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16014882" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bb0045" "etiqueta" => "9." "referencia" => array:1 [ 0 => array:1 [ "host" => array:1 [ 0 => array:1 [ "Libro" => array:4 [ "titulo" => "Orientações metodológicas para estudos de avaliação económica de medicamentos" "fecha" => "1999" "editorial" => "INFARMED" "editorialLocalizacion" => "Lisboa" ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bb0050" "etiqueta" => "10." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Resumo das Características do Medicamento ALIMTA®. Disponível em <a href="http://www.emea.europa.eu/humandocs/PDFs/EPAR/alimta/H-564-PI-pt.pdf">http://www.emea.europa.eu/humandocs/PDFs/EPAR/alimta/H-564-PI-pt.pdf</a>, consulta em Julho 2008." ] ] ] 10 => array:3 [ "identificador" => "bb0055" "etiqueta" => "11." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Resumo das Características do Medicamento TAXOTERE®. Disponível em <a href="http://www.emea.europa.eu/humandocs/PDFs/EPAR/taxotere/H-073-PI-pt.pdf">http://www.emea.europa.eu/humandocs/PDFs/EPAR/taxotere/H-073-PI-pt.pdf</a> consulta em Julho 2008." ] ] ] 11 => array:3 [ "identificador" => "bb0060" "etiqueta" => "12." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Contabilidade Analítica 2005, Hospitais do SNS. Ministério da Saúde, IGIF. Edição 2006." ] ] ] 12 => array:3 [ "identificador" => "bb0065" "etiqueta" => "13." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Infarmed [<a href="http://www.infarmed.pt/formulario/in-dex.html">http://www.infarmed.pt/formulario/in-dex.html</a>]." ] ] ] 13 => array:3 [ "identificador" => "bb0070" "etiqueta" => "14." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Diário da República, 1.ª série – N.º16, Portaria n.º 110-A/2007, de 23 de Janeiro de 2007." ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "pt" "url" => "/08732159/0000001400000006/v1_201509151433/S0873215915302889/v1_201509151433/pt/main.assets" "Apartado" => array:4 [ "identificador" => "9575" "tipo" => "SECCION" "pt" => array:2 [ "titulo" => "Artigos originais" "idiomaDefecto" => true ] "idiomaDefecto" => "pt" ] "PDF" => "https://static.elsevier.es/multimedia/08732159/0000001400000006/v1_201509151433/S0873215915302889/v1_201509151433/pt/main.pdf?idApp=UINPBA00004E&text.app=https://journalpulmonology.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0873215915302889?idApp=UINPBA00004E" ]
Original language: Portuguese
Year/Month | Html | Total | |
---|---|---|---|
2024 November | 6 | 3 | 9 |
2024 October | 40 | 34 | 74 |
2024 September | 28 | 36 | 64 |
2024 August | 51 | 51 | 102 |
2024 July | 49 | 37 | 86 |
2024 June | 40 | 28 | 68 |
2024 May | 58 | 34 | 92 |
2024 April | 50 | 25 | 75 |
2024 March | 33 | 27 | 60 |
2024 February | 31 | 27 | 58 |
2024 January | 24 | 21 | 45 |
2023 December | 19 | 41 | 60 |
2023 November | 20 | 23 | 43 |
2023 October | 27 | 57 | 84 |
2023 September | 33 | 32 | 65 |
2023 August | 36 | 21 | 57 |
2023 July | 47 | 36 | 83 |
2023 June | 32 | 16 | 48 |
2023 May | 52 | 26 | 78 |
2023 April | 16 | 20 | 36 |
2023 March | 43 | 15 | 58 |
2023 February | 65 | 32 | 97 |
2023 January | 36 | 20 | 56 |
2022 December | 29 | 23 | 52 |
2022 November | 45 | 40 | 85 |
2022 October | 34 | 31 | 65 |
2022 September | 29 | 30 | 59 |
2022 August | 24 | 49 | 73 |
2022 July | 20 | 37 | 57 |
2022 June | 28 | 30 | 58 |
2022 May | 41 | 31 | 72 |
2022 April | 34 | 41 | 75 |
2022 March | 16 | 28 | 44 |
2022 February | 26 | 24 | 50 |
2022 January | 32 | 37 | 69 |
2021 December | 20 | 37 | 57 |
2021 November | 24 | 33 | 57 |
2021 October | 40 | 34 | 74 |
2021 September | 32 | 29 | 61 |
2021 August | 18 | 24 | 42 |
2021 July | 27 | 26 | 53 |
2021 June | 20 | 24 | 44 |
2021 May | 35 | 33 | 68 |
2021 April | 31 | 53 | 84 |
2021 March | 36 | 30 | 66 |
2021 February | 50 | 13 | 63 |
2021 January | 25 | 9 | 34 |
2020 December | 32 | 12 | 44 |
2020 November | 35 | 18 | 53 |
2020 October | 20 | 12 | 32 |
2020 September | 74 | 28 | 102 |
2020 August | 40 | 14 | 54 |
2020 July | 73 | 28 | 101 |
2020 June | 57 | 15 | 72 |
2020 May | 53 | 20 | 73 |
2020 April | 51 | 21 | 72 |
2020 March | 47 | 15 | 62 |
2020 February | 45 | 19 | 64 |
2020 January | 50 | 17 | 67 |
2019 December | 39 | 23 | 62 |
2019 November | 62 | 21 | 83 |
2019 October | 35 | 17 | 52 |
2019 September | 47 | 30 | 77 |
2019 August | 88 | 18 | 106 |
2019 July | 62 | 18 | 80 |
2019 June | 70 | 13 | 83 |
2019 May | 87 | 37 | 124 |
2019 April | 78 | 29 | 107 |
2019 March | 103 | 14 | 117 |
2019 February | 110 | 22 | 132 |
2019 January | 96 | 26 | 122 |
2018 December | 32 | 10 | 42 |
2018 November | 20 | 1 | 21 |
2018 October | 31 | 7 | 38 |
2018 September | 26 | 8 | 34 |
2018 August | 48 | 29 | 77 |
2018 July | 48 | 21 | 69 |
2018 June | 67 | 17 | 84 |
2018 May | 89 | 20 | 109 |
2018 April | 68 | 36 | 104 |
2018 March | 77 | 36 | 113 |
2018 February | 61 | 12 | 73 |
2018 January | 68 | 17 | 85 |
2017 December | 91 | 18 | 109 |
2017 November | 50 | 13 | 63 |
2017 October | 25 | 18 | 43 |
2017 September | 32 | 7 | 39 |
2017 August | 36 | 13 | 49 |
2017 July | 36 | 11 | 47 |
2017 June | 31 | 13 | 44 |
2017 May | 36 | 20 | 56 |
2017 April | 8 | 4 | 12 |
2017 March | 12 | 28 | 40 |
2017 February | 13 | 5 | 18 |
2017 January | 15 | 8 | 23 |
2016 December | 11 | 5 | 16 |
2016 November | 8 | 4 | 12 |
2016 October | 11 | 8 | 19 |
2016 September | 3 | 5 | 8 |
2016 August | 4 | 2 | 6 |
2016 July | 4 | 5 | 9 |
2016 June | 0 | 4 | 4 |
2016 May | 2 | 4 | 6 |
2016 April | 2 | 4 | 6 |
2016 March | 1 | 5 | 6 |
2016 February | 5 | 6 | 11 |
2016 January | 5 | 5 | 10 |
2015 December | 9 | 1 | 10 |
2015 November | 3 | 5 | 8 |
2015 October | 2 | 2 | 4 |